Selecting Viruses for the Seasonal Influenza Vaccine
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

Selecting Viruses for the Seasonal Influenza Vaccine

Filetype[PDF-326.08 KB]


English
Details Supporting Files You May Also Like

Details:

  • Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.)
  • Description:
    All flu vaccine for 2024-2025 will be trivalent (three-component).

    Seasonal influenza (flu) vaccines are designed to protect against the four main groups of flu Type A and B viruses that research indicates are most likely to spread and cause illness among people during the upcoming flu season. All current U.S. flu vaccines protect against a flu A(H1) virus, a flu A(H3) virus, a flu B/Yamagata lineage virus and a flu B/Victoria lineage virus. Each of these four vaccine virus components are selected based on the following:

    • which flu viruses are making people sick prior to the upcoming flu season,

    • the extent to which those viruses are spreading prior to the upcoming flu season,

    • how well the previous season’s vaccines may protect against those flu viruses, and

    • the ability of vaccine viruses to provide cross-protection against a range of related flu viruses of the same type or subtype/lineage.

    There are currently 144 national influenza centers in over 114 countries that conduct year-round surveillance for flu viruses as part of the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS). This involves receiving and testing thousands of flu virus samples from patients. For human seasonal flu surveillance, the laboratories send representative viruses to five* of the seven WHO Collaborating Centers for Influenza, which are located in the following places:

    • Atlanta, Georgia, USA (Centers for Disease Control and Prevention, CDC)

    • Memphis, Tennessee, USA (St. Jude Children’s Research Hospital)

    • London, United Kingdom (The Francis Crick Institute)

    • Melbourne, Australia (Victoria Infectious Diseases Reference Laboratory)

    • Tokyo, Japan (National Institute for Infectious Diseases)

    • Beijing, China (National Institute for Viral Disease Control and Prevention)

    • Koltsovo, Russian Federation (State Research Center of Virology and Biotechnology “VECTOR,” Rospotrebnadzor)

    *Note: Two of the WHO Collaborating Centers: the one in Memphis, Tennessee and the one in Koltsovo, Russian Federation only collect flu virus specimens from animals and do not participate in human seasonal flu surveillance.

  • Content Notes:
    Summary -- Questions & Answers.
  • Subjects:
  • Document Type:
    Webpage
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov